[Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban].
Morishima
Yoshiyuki
Y
morishima.yoshiyuki.t4@daiichisankyo.co.jp
Shibano
Toshiro
T
D000284:Administration, Oral; D000818:Animals; D001281:Atrial Fibrillation / Q000150:complications; D017326:Clinical Trials, Phase III as Topic; D015195:Drug Design; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology; D006801:Humans; D020767:Intracranial Thrombosis / Q000209:etiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology; D055502:Secondary Prevention; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology; D013927:Thrombosis / Q000188:drug therapy*; D020246:Venous Thrombosis / Q000517:prevention & control
D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D011725:Pyridines; D013844:Thiazoles; C552171:edoxaban